About Vascular Therapies
Vascular Therapies: a focused, experienced, and passionate team driven by the goal of improving the lives of patients.
Vascular Therapies (VT) is a biopharmaceutical company committed to the development and commercialization of innovative new treatments to address major unmet clinical needs of patients requiring an AV fistula for dialysis. Our lead product candidate, containing sirolimus, has received orphan drug designations in the U.S. and E.U. for the dialysis vascular access indications.
The company consists of a focused, experienced, and passionate team driven by the goal of improving the lives of patients. We take pride in strong, global relationships with the patient, research, and medical communities.
The current development plan is focused on the hemodialysis vascular access indication – investigating the safety and usefulness of the drug product to improve the outcomes of an Arterio-Venous Fistula (AVF). The company is conducting its U.S. Phase 3 randomized, AVF clinical trial in accordance with a Special Protocol Assessment (SPA) Agreement with the U.S. FDA.
Meet our Management Team
Meet our Board of Directors
Caution: The Sirolimus-eluting Collagen Implant is an investigational product that is not available for sale in any country.
Read our Expanded Access Policy.